Iterum Therapeutics plc (NASDAQ:ITRM) finished Tuesday with a subtraction of -$0.02 to close at $0.52, a downside of -3.58 percent. An average of 9,793,840 shares of common stock have been traded in the last five days. There was a fall of -$0.0933 in the past week. The last 20 days have seen an average of 5,970,455 shares traded, while the 50-day average volume stands at 5,265,114.
ITRM stock has decreased by -22.30% in the last month. The company shares reached their 1-month lowest point of $0.5111 on 10/06/21. With the stock rallying to its 52-week high on 02/11/21, shares of the company touched a low of $0.45 and a high of $2.99 in 52 weeks. In spite of this, the price is down -82.74% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
237 days have passed since Iterum Therapeutics plc (ITRM) last reported insider trading activity. DENNER ALEXANDER J, who is 10% Owner, most recently acquired $10,619,949 shares at $2.27 per share on Feb 12. In this transaction, the insider spent $24,107,284. 10% Owner, DENNER ALEXANDER J, disposed of 10,000,000 shares at a price of $2.59 on Feb 11. The insider now owns more than $25,900,000 worth of shares. Prior to that, President & CEO Fishman Corey N. went on to Sale 85,445 shares at $1.73 each on Jan 26. An amount of $147,820 was transacted.
Iterum Therapeutics plc (ITRM) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 31.71 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 1.27. Other valuation ratios to consider include the price-to-book (PB) ratio at 1.99.
The quick ratio of Iterum Therapeutics plc for the three months ended June 29 was 2.80, and the current ratio was 2.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.44 and a total debt to equity ratio of 0.54 for the quarter ending June 29. Its gross profit as reported stood at $32.13 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Iterum Therapeutics plc’s return on assets was -163.40%.
For the three-month period that ended June 29, Iterum Therapeutics plc had $54.87 million in cash. The analyst consensus anticipated Iterum Therapeutics plc’s latest quarter earnings to come in at -$0.06 per share, but it turned out to be $0.04, a 166.70% surprise. For the quarter, EBITDA amounted to -$6.16 million. Shareholders own equity worth $182.78 million.
From a technical analysis perspective, let’s take a brief look at Iterum Therapeutics plc (ITRM) price momentum. RSI 9-day as of the close on 05 October was 35.00%, suggesting the stock is Neutral, with historical volatility in this time frame at 94.10%.
As of today, ITRM’s price is $0.5546 -15.29% or -$0.0933 from its 5-day moving average. ITRM is currently trading -20.33% lower than its 20-day SMA and -50.78% lower than its 100-day SMA. However, the stock’s current price level is -30.26% below the SMA50 and -42.26% below the SMA200.
The stochastic %K and %D were 10.00% and 22.38%, respectively, and the average true range (ATR) was 0.0478. With the 14-day stochastic at 3.62% and the average true range at 0.0494, the RSI (14) stands at 35.66%. The stock has reached -0.0209 on the 9-day MACD Oscillator while the 14-day reading was at -0.0295.
Gabelli & Co upgraded Iterum Therapeutics plc (NASDAQ: ITRM) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a a Sell.The consensus rating for Iterum Therapeutics plc (ITRM) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ITRM, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is ITRM’s price target for the next 12 months?
Analysts predict a range of price targets between $1.00 and $2.50, with a median target of $1.75. Taking a look at these predictions, the average price target given by analysts for Iterum Therapeutics plc (ITRM) stock is $1.75.